Temocillin in cystic fibrosis: A retrospective pilot study

Lisa Kent, Judy Bradley, Megan France, Gerd Doring, Stephane Carryn, Ian Bradbury, Jackie Rendall, Andrew Jones, J. Stuart Elborn

    Research output: Contribution to journalArticle

    9 Citations (Scopus)

    Abstract

    Background: Temocillin is currently used in the treatment of acute pulmonary exacerbations caused by Burkholderia cepacia complex and multi-resistant Pseudomonas aeruginosa in cystic fibrosis (CF) patients despite little published clinical data. This study assessed if intravenous (IV) antibiotic therapy including temocillin was equivalent to standard combination therapy for an acute exacerbation.MethodsA retrospective, pilot cross-over study. Adult patients attending two CF centres between 1997 and 2006 who had received a course of IV antibiotics including temocillin (TIV) and a further IV course (within ±1 year) which did not include temocillin (NTIV) were included. Outcome measures at the start and end of each IV course were recorded (FEV1%, FVC%).ResultsTwenty six patients had received temocillin. Baseline values of FEV1% predicted were comparable for both groups (TIV: 37(18%), NTIV: 39(20%)). FEV1% increased by 7.12(11.67)% after TIV (p
    LanguageEnglish
    Pages551-554
    JournalJournal of Cystic Fibrosis
    Volume7
    Issue number6
    DOIs
    Publication statusPublished - Nov 2008

    Fingerprint

    Cystic Fibrosis
    Retrospective Studies
    Burkholderia cepacia complex
    Anti-Bacterial Agents
    Cross-Over Studies
    Pseudomonas aeruginosa
    Therapeutics
    Outcome Assessment (Health Care)
    temocillin
    Lung

    Keywords

    • Temocillin
    • Burkholderia cepacia complex
    • Pseudomonas aeruginosa

    Cite this

    Kent, L., Bradley, J., France, M., Doring, G., Carryn, S., Bradbury, I., ... Elborn, J. S. (2008). Temocillin in cystic fibrosis: A retrospective pilot study. 7(6), 551-554. https://doi.org/10.1016/j.jcf.2008.06.005
    Kent, Lisa ; Bradley, Judy ; France, Megan ; Doring, Gerd ; Carryn, Stephane ; Bradbury, Ian ; Rendall, Jackie ; Jones, Andrew ; Elborn, J. Stuart. / Temocillin in cystic fibrosis: A retrospective pilot study. 2008 ; Vol. 7, No. 6. pp. 551-554.
    @article{6c98df672d8340b28e5c4874d4dfee51,
    title = "Temocillin in cystic fibrosis: A retrospective pilot study",
    abstract = "Background: Temocillin is currently used in the treatment of acute pulmonary exacerbations caused by Burkholderia cepacia complex and multi-resistant Pseudomonas aeruginosa in cystic fibrosis (CF) patients despite little published clinical data. This study assessed if intravenous (IV) antibiotic therapy including temocillin was equivalent to standard combination therapy for an acute exacerbation.MethodsA retrospective, pilot cross-over study. Adult patients attending two CF centres between 1997 and 2006 who had received a course of IV antibiotics including temocillin (TIV) and a further IV course (within ±1 year) which did not include temocillin (NTIV) were included. Outcome measures at the start and end of each IV course were recorded (FEV1{\%}, FVC{\%}).ResultsTwenty six patients had received temocillin. Baseline values of FEV1{\%} predicted were comparable for both groups (TIV: 37(18{\%}), NTIV: 39(20{\%})). FEV1{\%} increased by 7.12(11.67){\%} after TIV (p",
    keywords = "Temocillin, Burkholderia cepacia complex, Pseudomonas aeruginosa",
    author = "Lisa Kent and Judy Bradley and Megan France and Gerd Doring and Stephane Carryn and Ian Bradbury and Jackie Rendall and Andrew Jones and Elborn, {J. Stuart}",
    year = "2008",
    month = "11",
    doi = "10.1016/j.jcf.2008.06.005",
    language = "English",
    volume = "7",
    pages = "551--554",
    number = "6",

    }

    Kent, L, Bradley, J, France, M, Doring, G, Carryn, S, Bradbury, I, Rendall, J, Jones, A & Elborn, JS 2008, 'Temocillin in cystic fibrosis: A retrospective pilot study', vol. 7, no. 6, pp. 551-554. https://doi.org/10.1016/j.jcf.2008.06.005

    Temocillin in cystic fibrosis: A retrospective pilot study. / Kent, Lisa; Bradley, Judy; France, Megan; Doring, Gerd; Carryn, Stephane; Bradbury, Ian; Rendall, Jackie; Jones, Andrew; Elborn, J. Stuart.

    Vol. 7, No. 6, 11.2008, p. 551-554.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Temocillin in cystic fibrosis: A retrospective pilot study

    AU - Kent, Lisa

    AU - Bradley, Judy

    AU - France, Megan

    AU - Doring, Gerd

    AU - Carryn, Stephane

    AU - Bradbury, Ian

    AU - Rendall, Jackie

    AU - Jones, Andrew

    AU - Elborn, J. Stuart

    PY - 2008/11

    Y1 - 2008/11

    N2 - Background: Temocillin is currently used in the treatment of acute pulmonary exacerbations caused by Burkholderia cepacia complex and multi-resistant Pseudomonas aeruginosa in cystic fibrosis (CF) patients despite little published clinical data. This study assessed if intravenous (IV) antibiotic therapy including temocillin was equivalent to standard combination therapy for an acute exacerbation.MethodsA retrospective, pilot cross-over study. Adult patients attending two CF centres between 1997 and 2006 who had received a course of IV antibiotics including temocillin (TIV) and a further IV course (within ±1 year) which did not include temocillin (NTIV) were included. Outcome measures at the start and end of each IV course were recorded (FEV1%, FVC%).ResultsTwenty six patients had received temocillin. Baseline values of FEV1% predicted were comparable for both groups (TIV: 37(18%), NTIV: 39(20%)). FEV1% increased by 7.12(11.67)% after TIV (p

    AB - Background: Temocillin is currently used in the treatment of acute pulmonary exacerbations caused by Burkholderia cepacia complex and multi-resistant Pseudomonas aeruginosa in cystic fibrosis (CF) patients despite little published clinical data. This study assessed if intravenous (IV) antibiotic therapy including temocillin was equivalent to standard combination therapy for an acute exacerbation.MethodsA retrospective, pilot cross-over study. Adult patients attending two CF centres between 1997 and 2006 who had received a course of IV antibiotics including temocillin (TIV) and a further IV course (within ±1 year) which did not include temocillin (NTIV) were included. Outcome measures at the start and end of each IV course were recorded (FEV1%, FVC%).ResultsTwenty six patients had received temocillin. Baseline values of FEV1% predicted were comparable for both groups (TIV: 37(18%), NTIV: 39(20%)). FEV1% increased by 7.12(11.67)% after TIV (p

    KW - Temocillin

    KW - Burkholderia cepacia complex

    KW - Pseudomonas aeruginosa

    U2 - 10.1016/j.jcf.2008.06.005

    DO - 10.1016/j.jcf.2008.06.005

    M3 - Article

    VL - 7

    SP - 551

    EP - 554

    IS - 6

    ER -

    Kent L, Bradley J, France M, Doring G, Carryn S, Bradbury I et al. Temocillin in cystic fibrosis: A retrospective pilot study. 2008 Nov;7(6):551-554. https://doi.org/10.1016/j.jcf.2008.06.005